J&J/Merck says Pepcid AC onset of action is comparable to Tagamet HB in Sept. 5 suit.
This article was originally published in The Tan Sheet
Executive Summary
PEPCID AC ONSET OF ACTION COMPARABLE TO TAGAMET HB, J&J/MERCK ARGUES in a complaint filed Sept. 5 in District Court for the Southern District of New York. Based on "several" head-to-head comparisons between the two H2 antagonists, Johnson & Johnson/Merck maintained that "Pepcid AC and Tagamet HB have repeatedly been shown to work at the same rate of speed." J&J/Merck said it has conducted comparative assessments of the products in both acid control and symptom relief.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning